dipyridamole has been researched along with Reperfusion Injury in 18 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our findings show that the use of dipyridamole before testicular reperfusion has a potentially protective effect against long-term injury in testicular ischemia reperfusion injury." | 7.78 | Comparison of the protective effect of dipyridamole and acetylsalicylic acid on long-term histologic damage in a rat model of testicular ischemia-reperfusion injury. ( Karagüzel, E; Kazaz, İO; Kutlu, Ö; Mungan, S; Özgür, GK; Tok, DS; Yuluğ, E, 2012) |
| "One week of oral treatment with the nucleoside uptake inhibitor dipyridamole (200 mg, slow release, twice daily) significantly limits ischemia-reperfusion injury in humans in vivo, as assessed by technetium Tc 99m-labeled annexin A5 scintigraphy of forearm skeletal muscle." | 7.73 | Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. ( Boerman, OC; Engbersen, R; Oyen, WJ; Ramakers, BP; Riksen, NP; Rongen, GA; Smits, P; Van den Broek, PH, 2005) |
| "To investigate the protective mechanism of dipyridamole preconditioning against hepatic ischemia/reperfusion injury." | 7.73 | [Dipyridamole preconditioning protects against ischemia/reperfusion injury of rat liver]. ( Hong, Y; Liao, WS; Mo, RX, 2006) |
| "We demonstrated marked hepatoprotective effects of dipyridamole against severe ischemia and reperfusion injury in canine livers." | 7.72 | Dipyridamole protects the liver against warm ischemia and reperfusion injury. ( Furukawa, H; Iida, J; Jin, MB; Magata, S; Shimamura, T; Suzuki, T; Taniguchi, M; Todo, S, 2004) |
| "Dipyridamole (DYP) is an anti-platelet agent with marked vasodilator, anti-oxidant, and anti-inflammatory activity." | 5.43 | Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats. ( Buttar, HS; Kaur, T; Mohey, V; Pathak, D; Puri, N; Singh, AP; Singh, M, 2016) |
| "Rosuvastatin increases extracellular adenosine formation, which provides protection against ischemia-reperfusion injury in humans in vivo." | 5.14 | Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. ( Boerman, OC; Dekker, D; Meijer, P; Oyen, WJ; Rongen, GA; Scheffer, GJ; Smits, P; van den Broek, PH; Wouters, CW, 2009) |
| "Our findings show that the use of dipyridamole before testicular reperfusion has a potentially protective effect against long-term injury in testicular ischemia reperfusion injury." | 3.78 | Comparison of the protective effect of dipyridamole and acetylsalicylic acid on long-term histologic damage in a rat model of testicular ischemia-reperfusion injury. ( Karagüzel, E; Kazaz, İO; Kutlu, Ö; Mungan, S; Özgür, GK; Tok, DS; Yuluğ, E, 2012) |
| "One week of oral treatment with the nucleoside uptake inhibitor dipyridamole (200 mg, slow release, twice daily) significantly limits ischemia-reperfusion injury in humans in vivo, as assessed by technetium Tc 99m-labeled annexin A5 scintigraphy of forearm skeletal muscle." | 3.73 | Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. ( Boerman, OC; Engbersen, R; Oyen, WJ; Ramakers, BP; Riksen, NP; Rongen, GA; Smits, P; Van den Broek, PH, 2005) |
| "To investigate the protective mechanism of dipyridamole preconditioning against hepatic ischemia/reperfusion injury." | 3.73 | [Dipyridamole preconditioning protects against ischemia/reperfusion injury of rat liver]. ( Hong, Y; Liao, WS; Mo, RX, 2006) |
| "We demonstrated marked hepatoprotective effects of dipyridamole against severe ischemia and reperfusion injury in canine livers." | 3.72 | Dipyridamole protects the liver against warm ischemia and reperfusion injury. ( Furukawa, H; Iida, J; Jin, MB; Magata, S; Shimamura, T; Suzuki, T; Taniguchi, M; Todo, S, 2004) |
| "We examined the effect of 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine (ibudilast), which has been clinically used for bronchial asthma and cerebrovascular disorders, on cell viability induced in a model of reperfusion injury." | 3.71 | Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model. ( Baba, A; Enomoto, R; Lee, E; Matsuda, T; Mori, K; Takuma, K, 2001) |
| " Therefore, it was aimed to study whether dipyridamole (CAS 58-32-2), an adenosine uptake inhibitor, or adenosine (CAS 58-61-7) could affect the rat brain gamma-aminobutyric acid (GABA, CAS 56-12-2) level after induction of cerebral ischemia, and to test their effect on the lactate dehydrogenase (LDH) activity of the ischemic rat brain." | 3.71 | Influence of inhibition of adenosine uptake on the gamma-aminobutyric acid level of the ischemic rat brain. ( Khattab, M; Seif-el-Nasr, M, 2002) |
| "Dipyridamole (DYP) is an anti-platelet agent with marked vasodilator, anti-oxidant, and anti-inflammatory activity." | 1.43 | Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats. ( Buttar, HS; Kaur, T; Mohey, V; Pathak, D; Puri, N; Singh, AP; Singh, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 12 (66.67) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zimmerman, MA | 1 |
| Tak, E | 1 |
| Ehrentraut, SF | 1 |
| Kaplan, M | 1 |
| Giebler, A | 1 |
| Weng, T | 1 |
| Choi, DS | 1 |
| Blackburn, MR | 1 |
| Kam, I | 1 |
| Eltzschig, HK | 1 |
| Grenz, A | 1 |
| Puri, N | 1 |
| Mohey, V | 1 |
| Singh, M | 1 |
| Kaur, T | 1 |
| Pathak, D | 1 |
| Buttar, HS | 1 |
| Singh, AP | 1 |
| Meijer, P | 1 |
| Oyen, WJ | 3 |
| Dekker, D | 1 |
| van den Broek, PH | 2 |
| Wouters, CW | 1 |
| Boerman, OC | 3 |
| Scheffer, GJ | 1 |
| Smits, P | 3 |
| Rongen, GA | 3 |
| Karagüzel, E | 1 |
| Kutlu, Ö | 1 |
| Yuluğ, E | 1 |
| Mungan, S | 1 |
| Kazaz, İO | 1 |
| Tok, DS | 1 |
| Özgür, GK | 1 |
| Kosieradzki, M | 1 |
| Ametani, M | 1 |
| Southard, JH | 1 |
| Mangino, MJ | 1 |
| Taniguchi, M | 1 |
| Magata, S | 1 |
| Suzuki, T | 1 |
| Shimamura, T | 1 |
| Jin, MB | 1 |
| Iida, J | 1 |
| Furukawa, H | 1 |
| Todo, S | 1 |
| Yamagata, K | 1 |
| Ichinose, S | 1 |
| Tagami, M | 1 |
| Riksen, NP | 2 |
| Ramakers, BP | 1 |
| Engbersen, R | 1 |
| Hong, Y | 1 |
| Liao, WS | 1 |
| Mo, RX | 1 |
| Franke, B | 1 |
| Borm, GF | 1 |
| van den Broek, P | 1 |
| Iba, T | 1 |
| Howell, JG | 2 |
| Zibari, GB | 2 |
| Brown, MF | 2 |
| Burney, DL | 1 |
| Sawaya, DE | 1 |
| Olinde, JG | 2 |
| Granger, DN | 2 |
| McDonald, JC | 2 |
| Akgür, FM | 1 |
| Takuma, K | 1 |
| Lee, E | 1 |
| Enomoto, R | 1 |
| Mori, K | 1 |
| Baba, A | 1 |
| Matsuda, T | 1 |
| Seif-el-Nasr, M | 1 |
| Khattab, M | 1 |
| De La Cruz, JP | 1 |
| Villalobos, MA | 1 |
| Carrasco, T | 1 |
| Smith-Agreda, JM | 1 |
| Sánchez de la Cuesta, F | 1 |
| Kaminski, PM | 1 |
| Proctor, KG | 1 |
| Hornsey, S | 1 |
| Myers, R | 1 |
| Jenkinson, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Does Rosuvastatin Reduce Ischemia/Reperfusion Injury in Humans In-Vivo? A Randomized Double Blind Placebo Controlled Trial[NCT00315510] | Phase 2 | 20 participants | Interventional | 2006-04-30 | Completed | ||
| Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?[NCT00457652] | Phase 4 | 24 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Rosuvastatin Augments Dipyridamole Induced Vasodilation by Increased Adenosine Receptor Stimulation.[NCT00554138] | 24 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury[NCT00987974] | Phase 4 | 48 participants (Anticipated) | Interventional | 2009-09-30 | Completed | ||
| Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?[NCT00457405] | Phase 4 | 10 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?[NCT00430170] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)[NCT02714036] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-05-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dipyridamole and Reperfusion Injury
| Article | Year |
|---|---|
[Pretreatment with cilostazol protects against the vascular endothelial damage after ischemia/reperfusion].
Topics: Animals; Aspirin; Cilostazol; Dipyridamole; Endothelial Cells; Ischemic Preconditioning; Mice; Phosp | 2008 |
1 trial available for dipyridamole and Reperfusion Injury
| Article | Year |
|---|---|
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
16 other studies available for dipyridamole and Reperfusion Injury
| Article | Year |
|---|---|
Equilibrative nucleoside transporter (ENT)-1-dependent elevation of extracellular adenosine protects the liver during ischemia and reperfusion.
Topics: Adenosine; Animals; Dipyridamole; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside T | 2013 |
Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats.
Topics: Acute Kidney Injury; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Adenosine A2 | 2016 |
Comparison of the protective effect of dipyridamole and acetylsalicylic acid on long-term histologic damage in a rat model of testicular ischemia-reperfusion injury.
Topics: Animals; Apoptosis; Aspirin; Dipyridamole; Disease Models, Animal; Drug Administration Schedule; In | 2012 |
Is ischemic preconditioning of the kidney clinically relevant?
Topics: Animals; Cold Temperature; Dipyridamole; Disease Models, Animal; Dogs; Glomerular Filtration Rate; H | 2003 |
Dipyridamole protects the liver against warm ischemia and reperfusion injury.
Topics: Animals; Blood Pressure; Cyclic AMP; Dipyridamole; Disease Models, Animal; Dogs; Energy Metabolism; | 2004 |
Amlodipine and carvedilol prevent cytotoxicity in cortical neurons isolated from stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antioxidants; Carbazoles; Carvedilol; Cell Death; Cell Hypoxia; Cells, Cultured | 2004 |
Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.
Topics: Administration, Oral; Adult; Annexin A5; Blood Pressure; Caffeine; Dipyridamole; Drug Administration | 2005 |
Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.
Topics: Administration, Oral; Adult; Annexin A5; Blood Pressure; Caffeine; Dipyridamole; Drug Administration | 2005 |
Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.
Topics: Administration, Oral; Adult; Annexin A5; Blood Pressure; Caffeine; Dipyridamole; Drug Administration | 2005 |
Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.
Topics: Administration, Oral; Adult; Annexin A5; Blood Pressure; Caffeine; Dipyridamole; Drug Administration | 2005 |
[Dipyridamole preconditioning protects against ischemia/reperfusion injury of rat liver].
Topics: Animals; Dipyridamole; Disease Models, Animal; Female; Ischemic Preconditioning; Liver; Male; Random | 2006 |
Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene.
Topics: Adult; AMP Deaminase; Dipyridamole; Female; Forearm; Humans; Hyperemia; Ligation; Male; Reperfusion | 2007 |
Both ischemic and pharmacological preconditioning decrease hepatic leukocyte/endothelial cell interactions.
Topics: Animals; Aspartate Aminotransferases; Cell Adhesion; Dipyridamole; Endothelium, Vascular; Ischemic P | 2000 |
Persantine attenuates hemorrhagic shock-induced P-selectin expression.
Topics: Adenosine; Animals; Colon; Dipyridamole; Disease Models, Animal; Drug Evaluation, Preclinical; Intes | 2000 |
Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model.
Topics: Alkaloids; Animals; Animals, Newborn; Apoptosis; Astrocytes; Carbazoles; Cell Survival; Cyclic GMP; | 2001 |
Influence of inhibition of adenosine uptake on the gamma-aminobutyric acid level of the ischemic rat brain.
Topics: Adenosine; Animals; Biomarkers; Brain; Brain Chemistry; Brain Ischemia; Cerebral Cortex; Dipyridamol | 2002 |
The pyrimido-pyrimidine derivative RA-642 protects from brain injury in a combined model of permanent focal ischemia and global ischemia reperfusion.
Topics: Animals; Brain; Dipyridamole; Disease Models, Animal; Ischemic Attack, Transient; Lipid Peroxidation | 1992 |
Extracellular and intracellular actions of adenosine and related compounds in the reperfused rat intestine.
Topics: 2-Chloroadenosine; Adenosine; Aminoimidazole Carboxamide; Animals; Dipyridamole; Intestines; Male; P | 1992 |
The reduction of radiation damage to the spinal cord by post-irradiation administration of vasoactive drugs.
Topics: Animals; Deferoxamine; Dipyridamole; Male; Necrosis; Radiation Injuries, Experimental; Rats; Reperfu | 1990 |